(IN BRIEF) The Royal Devon University Healthcare NHS Foundation Trust and the University of Exeter have launched the RAPID-IBD study to speed up diagnosis of Crohn’s disease and ulcerative colitis, conditions that affect 1 in 100 people in the UK. … Read the full press release
Posted in Education, Healthcare, Pharma & Biotech, Science, Sports, Technology, United Kingdom
Tagged Catherine Winsor, Crohn's disease, Crohn’s & Colitis UK, early diagnosis, EX postcode, Exeter City FC, gut health, IBD, inflammatory bowel disease, Jack Fitzwater, Know Your Sh*t campaign, Know Your Sh*t Campaign Backs Exeter-Led Study to Improve Early Detection of IBD in Young People, New Exeter Research Aims to Transform Diagnosis and Treatment Pathways for Crohn’s and Colitis, NIHR, patient volunteers, RAPID-IBD, RAPID-IBD Research Project Invites Volunteers to Speed Up Diagnosis of Inflammatory Bowel Disease, Royal Devon University Healthcare NHS Foundation Trust, stool test, Tariq Ahmad, Ulcerative colitis, University of Exeter
(IN BRIEF) Fresenius Kabi has licensed rights from Polpharma Biologics to commercialize the vedolizumab biosimilar candidate PB016 globally—except in the Middle East and North Africa—once approved. Vedolizumab treats Crohn’s disease and ulcerative colitis, and PB016 references Takeda’s Entyvio®. The transaction … Read the full press release
Posted in Business, Financial, Germany, Government, Healthcare, Industrial, Investment, Management, Marketing, News, Pharma & Biotech, Poland, Science, Technology
Tagged #FutureFresenius, (Bio)Pharma portfolio, chronic inflammatory diseases, Crohn's disease, denosumab biosimilar, Dr. Sang-Jin Pak, EC Approval, Entyvio, FDA approval, Fresenius Kabi, global commercialization, Konstantin Matentzoglu, licensing agreement, partnership, PB016, Polpharma Biologics S.A., Ulcerative colitis, Ustekinumab Biosimilar, vedolizumab biosimilar
(IN BRIEF) Sanofi and Teva Pharmaceuticals have announced a collaboration to co-develop and co-commercialize TEV’574, a promising asset currently in Phase 2b clinical trials for the treatment of Ulcerative Colitis and Crohn’s Disease, both forms of inflammatory bowel disease (IBD). … Read the full press release
Posted in Business, Environment, Financial, France, Healthcare, Industrial, Investment, Management, News, Pharma & Biotech, Science
Tagged Anti-TL1As, Crohn's disease, in $1.5 Billion Deal, Inflammatory Bowel Disease Treatment, partnership, Paul Hudson, Richard Francis, Sanofi, sustainability, Teva, TEV’574, Ulcerative colitis, wellness
Clinicians at the University Hospital Erlangen show how a new laser-based imaging technique termed MSOT can detect inflammation more accurately than current non-invasive diagnostic procedures and thereby help reduce the burden to patients MUNICH, 30-Mar-2017 — /EuropaWire/ — Ulcerative colitis … Read the full press release
Posted in France, Germany, Healthcare, Italy, Netherlands, News, Pharma & Biotech, Science, Technology, United Kingdom
Tagged Christian Wiest, Clinicians, Crohn's disease, Crohn's disease patients, detection of melanoma metastasis, diagnosis, diagnostic imaging, Dr. Ferdinand Knieling, hemoglobin values, IBD, inflammation, inflammatory bowel disease, intestinal mucosa, invasive endoscopy procedure, iThera Medical, laser light, laser-based imaging technique, medical device, medical imaging, MSOT, MSOT technology, Multspectral Optoacoustic Tomography, new diagnostic imaging modality, New England Journal of Medicine, non-invasive assessment, optoacoustic, optoacoustic imaging, photoacoustic, Prof. Dr. Maximilian Waldner, sentinel lymph nodes, suspicious breast lesions, Ulcerative colitis, ultrasound, University Hospital Erlangen
EuropaWire (EW) is the first truly pan-European and leading press release distribution and newswire service for Europe and the European Union working towards consolidating Europe’s voice on the global newswire and media scene. The newswire service comes with advanced submission forms, flexible pricing and PR budgeting, granular targeting, nearly uncapped reach across countries, markets, verticals, industries, audiences, languages, etc., translation and localisation for greater local PR impact, in-depth distribution reporting, metrics and insights including measured PR reach, reads, engagements, impact, etc., no cap on words, images and multimedia to go along with your release, among others. Your press releases will be seen among the releases of Europe’s biggest and most prominent companies, brands and institutions. Here you can learn more about EuropaWire’s mission, achievements, services, etc.
HOW TO GET STARTED?